• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / Citizens Speak / HPV Vax / United States Concerns / SANE Vax to CDC: Request for additional data on HPV vaccine post-marketing monitoring

SANE Vax to CDC: Request for additional data on HPV vaccine post-marketing monitoring

August 31, 2011 By Norma 1 Comment

Lauri Markowitz, M.D.
Centers for Disease Control and Prevention
MS E05, 1600 Clifton Road
Atlanta, GA 30333
lem2@cdc.govAugust 31, 2011

Dear Dr. Markowitz:

Thank you for your August 29, 2011 response to my letter requesting additional information about post licensure monitoring for Gardasil™ from the CDC. Before relaying your response to medical consumers, I would like to ask you to clarify the following two points.

1)       Your letter stated: ‘In Australia…some decreases in HPV associated outcomes have been observed already.’ May I ask you to provide a published reference to support this statement? The only paper I have read from Australia on this issue is an article by Brotherton et al. [1] in which the authors stated ‘we recorded a decrease in the incidence of HGAs by 0.38%.’ According to the authors, HCAs were lesions coded as CIN2 or worse. Since CIN2 is not a true biologic entity [2] and 25-50% of the CIN2 lesions are self-resolving [3] a 0.38% decrease of CIN2 lesions with a self-resolving rate of up to 50% can hardly be used as convincing evidence for demonstrating the efficacy of a vaccine approved to prevent cervical cancer in the decades to come.
Furthermore, there appeared to be no HPV genotyping data in the Brotherton paper. [1] As a result, there were no HPV associated outcomes in their study. I assume you must have another Australian reference to support your statement. If you do, please provide the reference.

2)      The HPV genotype distribution in the table attached to your letter seems to show highly contradictory results between the states. For example, the numbers of HPV-16 and HPV-18 infections in 2009 may well exceed the numbers infected by these two genotypes in 2008 in Oregon and Tennessee while the data in California, Connecticut and New York may show a decrease in HPV-16 and HPV-18 infections. I am wondering if the discrepancy in efficacy results in different states might be due to a lack of a common denominator or varying method being used for HPV genotyping.

 According to a group of experts on HPV testing, ‘To meet currently achievable standards, the test should have a clinical sensitivity to detect at least 92% ± 3% of CIN 3+ …and the test should have clinical specificity of at least 85% such that adequate positive predictive value for CIN 3…’ [4]

Therefore, I would like to have elaboration on:

  • Whether the CDC requires all states to use CIN3 lesions as the common denominator in tabulating the numbers of infections by various individual HPV genotypes?
  • Does the CDC require all the methods used for HPV testing by these states to meet the clinical sensitivity to detect at least 92% of CIN3 lesions and the clinical specificity of at least 85% for CIN 3?

I am looking forward to receiving your kind clarification.

Norma Erickson, President

SANE Vax Inc.
154 Cecil Drive
Troy Montana, 59935

References:

[1] Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011; 377:2085-92.

[2] Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007;127:805-815.

[3] Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol. 2010;171:155-63.

[4] Stoler MH, Castle PE, Solomon D, Schiffman M. The Expanded Use of HPV Testing in Gynecologic Practice per ASCCP-Guided Management Requires the Use of Well-Validated Assays. Am J Clin Pathol. 2007;127:1-3.

The following response was received from Dr. Lauri Markowitz via email on 21 Sept 2011:

Ms. Erickson,

Data from Australia on decreases in HPV-associated outcomes include mainly ecologic data on declines in genital warts. From Donovan et al. Lancet Infect Dis 2011:  “After vaccination began, a decline in number of diagnoses of genital warts was noted for young female residents (59%, p(trend)<0·0001). No significant decline was noted in female non-residents, women older than 26 years in July, 2007, or in men who have sex with men. However, proportionally fewer heterosexual men were diagnosed with genital warts during the vaccine period (28%, p(trend)<0·0001).”  The data on trends in cervical precancer lesions from Australia show minimal declines, as you stated, and there are no genotyping data.

Concerning the genotyping data we shared with you from the U.S, these are preliminary data. We do not have complete data from the states yet and it is not possible to compare between states.  We eventually will be able to do so.  All genotyping is done by the same method at CDC.  The methods were shared with you in a previous letter.

Sincerely,
Lauri Markowitz, M.D.
 
 
 
 
 
 

Related

Filed Under: United States Concerns Tagged With: CDC, Dr. Markowitz, HPV genotyping, HPV prevalence, HPV vaccination, post-licensure monitoring

Trackbacks

  1. SANE Vax to CDC: Request for additional data on HPV vaccine post-marketing monitoring | ONE MORE GIRL says:
    May 6, 2013 at 4:20 pm

    […] Read letter here: […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Sarah from the UK

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

before after gardasil

Kenzie Before After Gardasil. The Story of Kenzie

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in

 

Loading Comments...